Recurrence and progression in non-muscle-invasive bladder cancer using EORTC risk tables

Urologia Internationalis

Volumn 89, Issue 1, 2012, Pages 61-66

  Altieri, Vincenzo Maria ^a,c   Castellucci, Roberto ^a   Palumbo, Pietro ^a   Verratti, Vittore ^a   Sut, Michal ^b   Olivieri, Raffaella ^a   Manco, Rossella ^a   Ricciardulli, Stefano ^a   Nicolai, Michele ^a   Criniti, Pasquale ^a   Tenaglia, Raffaele Lanfranco ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b BEDFORD HOSPITAL NHS TRUST   (United Kingdom)

^c NONE   (Italy)

Author keywords

Chemotherapy; Immunotherapy; Non muscle invasive bladder cancer; Second transurethral resection; Transurethral resection of the bladder

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CLINICAL PRACTICE; CONTROLLED STUDY; CYSTECTOMY; DISEASE SEVERITY; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER RISK TABLE; FEMALE; FOLLOW UP; HEMATURIA; HUMAN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; SCORING SYSTEM; TRANSURETHRAL RESECTION; TREATMENT FAILURE;

EID: 84864615986     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000336516     Document Type: Article

References (19)

1. Parkin DM: The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl 2008; 218:12-20.
2. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Ca ncer J Clin 2008; 58: 71-96. (Pubitemid 351521864)
3. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauster R: The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003; 21:1315-1330. (Pubitemid 38041357)
4. Kirkali Z, Chan T, Manoharan M, et al: Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005; 66(suppl 6A):4-34. (Pubitemid 43049607)
5. Sylvester RJ, van der Meijden AP, Lamm DL: Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168: 1964-1970.
6. Oosterlinck W, Lobel B, Jakse G, Malmström PU, Stöckle M, Sternberg C, the European Association of Urology Working Group on Oncological Urology: Guidelines on bladder cancer. Eur Urol 2002; 41:105-112.
7. Riley GF, Potosky AL, Lubitz JD, Kessler LG: Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995; 33: 828-841.
8. Sylvester RJ, Adrian PM, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DWW, Kurth K: Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49:466-477.
9. Sobin DH, Wittekind Ch (eds): TNM Classification of Malignant Tumours, ed 6. New York, Wiley-Liss, 2002, pp 199-202.
10. Babjuk M, Oosterlinck W, Sylvester R, Kaas-inen E, Böhle A, Palou J, Rouprê M: Guidelines on non-muscle invasive bladder cancer (TaT1 and CIS). Arnhem, European Association of Urology, 2011, pp 4-35.
11. Murta-Nascimento C, Schmitz-Dräger BJ, Zeegers MP, et al: Epidemiology of urinary bladder cancer: from tumour development to patient's death. World J Urol 2007; 25:285-295.
12. Babjuk M, Oosterlinck W, Sylvester R, Kaas-inen E, Böhle A, Palou-Redorta J: EAU guidelines on non-muscle-invasive urothe-lial carcinoma of the bladder. Eur Urol 2008; 54: 303-314.
13. Böhle A, Jocham D, Bock PR: Int ravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal me-ta-analysis of comparative studies on recurrence and toxicity. J Urol 2003; 169:90-95. (Pubitemid 35461559)
14. Divrik RT, Sahin AF, Yildirim Ü, Altok M, Zorlu F: Impact of routine second transure-thral resection on the long-term outcome of patients with newly diagnosed pT1 urothe-lial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomized clinical tria l. Eur Urol 2010; 58: 185-190.
15. Rodríguez Alonso A, Pita Fernández S, González- Carreró J, Nogueira March JL: Multivariate analysis of recurrence and progression in stage T1 transitional-cell carcinoma of the bladder. Prognostic value of p53 a nd Ki67. Actas Urol Esp 2003; 27: 132-141. (Pubitemid 36389338)
16. Baak JP, Bol MG, van Diermen B, Janssen EA, Buhr-Wildhagen SB, Mestad O, Øgreid P, Kjellevold KH: DNA cytometric features i n biopsies of TaT1 u rot helia l cel l c a ncer predict recurrence and stage progression more accurately than stage, grade, or treatment modality. Urology 2003; 61:1266-1272. (Pubitemid 36694031)
17. van Rhijn BW, Zuiverloon TC, Vis AN, Rad-vanyi F, van Leenders GJ, Ooms BC, Kirkels WJ, Lockwood GA, Boevé ER, Jöbsis AC, Zwarthoff EC, van der Kwast TH: Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol 2010; 58: 433-441.
18. Baak JP, Bol MG, van Diermen B, Janssen EA, Buhr-Wildhagen SB, Mestad O, Øgreid P, Kjellevold KH: DNA cytometric features i n biopsie s of TaT1 u rot hel ia l c el l ca ncer pre-dict recurrence and stage progression more accurately than stage, grade, or treatment modality. Urology 2003; 61:1266-1272. (Pubitemid 36694031)
19. Gupta NP, Sharma N, Kumar R: Nuclear matrix protein 22 as adjunct to urine cytology and cystoscopy in follow-up of superficial TCC of urinary bladder. Urolog y 2009; 73: 592-596.